Drug Search Results
More Filters [+]

Derenofylline

Alternative Names: derenofylline, slv320
Latest Update: 2010-09-17
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: ADORA1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Solvay Pharm
Company Location: 1120 BRUSSELS C9 00000
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Derenofylline

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Kidney Diseases|Heart Failure, Acute|Acute Kidney Injury|Heart Failure|Heart Failure, Chronic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2008-003786-20

P2

Terminated

Heart Failure, Acute

2010-01-04

Reno-Defend 1

P2

Terminated

Acute Kidney Injury|Heart Failure, Acute|Kidney Diseases

2010-01-01

2007-000490-40

P2

Completed

Kidney Diseases|Heart Failure, Chronic

2009-03-20

S320.2.003

N/A

Terminated

Kidney Diseases|Heart Failure

2008-11-01

Recent News Events

Date

Type

Title